DELAQUA PHARMACEUTICALS INC

Biotech · Private

Polymeric micelle platform for enhancing solubility and bioavailability of hydrophobic drugs

Grants
$275K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Triblock copolymer micelles for enhanced drug solubilization and stability$275,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3077CELETRIX, LLC——
3078Myeloid Therapeutics——
3079Cardior Pharmaceuticals——
3080DELAQUA PHARMACEUTICALS INC——
3081DETECTOGEN, INC.——
3082Altigg Therapeutics, Inc.——
3083Ventus Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Polyoxazoline Micellar Pharmaceutical Compositionsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.